Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIANE
2023-505945-19-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2 trial of ipilimumab and nivolumab in melanoma, sponsored by Netherlands Cancer Institute. Planned start Feb 2024; status: authorised.
02
Drugs
ipilimumabnivolumab
03
Conditions
melanoma
Beyond the preview
Go deeper on 2023-505945-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505945-19-00.